Condition: Breast Cancer Early Stage Breast Cancer (Stage 1-3) · Breast Cancer Metastatic · Ovarian Cancer · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.
This description comes directly from the study's public registry record.
Claudio Zamagni, MD · 0512144548 · zamagniclaudio.sper@aosp.bo.it
Cinzia Pizzirani, PhD · 0512144447 · cinzia.pizzirani@aosp.bo.it
Always discuss trial participation with your own doctor first.
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06800612